Sotigalimab and/or nivolumab with chemotherapy in first-line metastatic pancreatic cancer: clinical and immunologic analyses from the randomized phase 2 PRINCE trial
Lacey J. Padrón, Deena M. Maurer, Mark H. O’Hara, Eileen M. O’Reilly, Robert A. Wolff, Zev A. Wainberg, Andrew H. Ko, George Fisher, Osama Rahma, Jaclyn P. Lyman, Christopher R. Cabanski, Jia Xin Yu, Shannon M. Pfeiffer, Marko Spasic, Jingying Xu, Pier Federico Gherardini, Joyson Karakunnel, Rosemarie Mick, Cécile Alanio, Katelyn T. ByrneTravis J. Hollmann, Jonni S. Moore, Derek D. Jones, Marco Tognetti, Richard O. Chen, Xiaodong Yang, Lisa Salvador, E. John Wherry, Ute Dugan, Jill O’Donnell-Tormey, Lisa H. Butterfield, Vanessa M. Hubbard-Lucey, Ramy Ibrahim, Justin Fairchild, Samantha Bucktrout, Theresa M. LaVallee, Robert H. Vonderheide
Research output: Contribution to journal › Article › peer-review
Dive into the research topics of 'Sotigalimab and/or nivolumab with chemotherapy in first-line metastatic pancreatic cancer: clinical and immunologic analyses from the randomized phase 2 PRINCE trial'. Together they form a unique fingerprint.